← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neurogt, Inc.
Chapel Hill, NC
$7,272,902
Total funding
6
Grants
Funding over time
peak $4.1M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,272,902 · 6
By mechanism
R44$5,538,061 · 3
R41$1,734,841 · 3
Investigators at Neurogt, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I$1,499,504
R44 · FY2025 · NS
Development of gene therapy product for treating MPS IIIB$1,305,826
R44 · FY2025 · NS
Protein depleting pre-existing antibodies for viral gene therapy$1,000,000
R44 · FY2024 · AI
Protein depleting pre-existing antibodies for viral gene therapy$969,817
R44 · FY2025 · AI
Development of gene therapy product for treating MPS IIIB$456,414
R44 · FY2024 · NS
Development of gene therapy product for treating MPS IIIB$397,823
R41 · FY2020 · NS
Develop AAV9 gene replacement therapy for treating MPS I$378,882
R41 · FY2022 · NS
Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC$349,909
R41 · FY2025 · NS
Develop AAV9 gene replacement therapy for treating MPS I$323,802
R41 · FY2023 · NS
Protein depleting pre-existing antibodies for viral gene therapy$306,500
R44 · FY2023 · AI
Development of gene therapy product for treating MPS IIIB$284,425
R41 · FY2021 · NS